


# MODELLING THE EFFECT OF SYMMETRICAL DIVISION OF CANCER STEM CELLS ON TUMOUR RESPONSE TO RADIATION

**Loredana G. Marcu<sup>1,2</sup> & David Marcu<sup>1</sup>**

*Faculty of Science, University of Oradea, Romania &  
School of Physical Sciences, The University of Adelaide, Australia*



# CHALLENGES IN THE MANAGEMENT OF HEAD&NECK TUMOURS\*

## Clinical challenges:

- preservation of critical organ function
- management of treatment side-effects
- timing of multimodality treatments

## Radiobiological challenges:

- tumour hypoxia
- accelerated repopulation of tumour cells during treatment

\* L. Marcu & E. Yeoh **2009** *J Cancer Res & Clin Oncol* 135(10):1303-1314

# PREDICTIVE ASSAYS FOR TUMOURS

**Aim:** to choose a treatment protocol that is optimal for each individual patient.

**Classification of assays:**

- oxygen status
- proliferative potential
- intrinsic cellular radiosensitivity


**HOWEVER:** despite some promising *in vitro* results, the large majority of predictive assays have failed during *in vivo* testing.

E. Hall *Radiobiology for the radiologist* 7<sup>th</sup> ed – “... we considered omitting the chapter on predictive assays because they have yet to justify their early promise”.

# FROM PREDICTIVE ASSAYS TO *IN SILICO* MODELLING

## MODELS:

- allow predictive assessment of the multi-parameter processes that govern radiotherapy outcome
- allow quantitative treatment optimisation
- answer to “what if” questions



L. Marcu et al 2002 *Australas Phys Eng Sci Med* 25:155-161

# MODELLING AIMS (I)

To grow a **virtual HNC** with biologically realistic parameters.

To include **CSC** in the model\* and implement their **properties** based on literature findings.


To **evaluate the effect of CSC division pattern** on tumour response to radiotherapy under hypoxic conditions.

\* L. Marcu & E. Bezak **2012** *Cell Prolif* 45(5):404-412

# CURRENT TREATMENT CHALLENGES: CANCER STEM CELLS

Cancer stem cells (CSC) are a subpopulation of cells originating from stem cells and have the following properties<sup>1</sup>:

- are long lived,
- have the ability to proliferate indefinitely
- can generate all heterogeneous lineages of the original tumour
- can recreate themselves by symmetric division<sup>2</sup>
- are more radioresistant than non-stem cancer cells<sup>3</sup>
- they preferentially reside in special microenvironmental niches within the tumour<sup>4</sup>



Nature Med 14, 814 (2008) doi:10.1038/nm0808-814

<sup>1</sup> N. Moore et al **2011** *J Oncology* 396076

<sup>2</sup> S. Morrison et al **2006** *Nature* 441, 1068

<sup>3</sup> D. Ramirez-Guerrero **2015** AAAS abstract

<sup>4</sup> C. Peitzsch et al **2014** *Int J Radiat Biol* 90, 636

# HEAD & NECK TUMOUR GROWTH MODEL DURING RT

Cell kinetic parameter	Mean value (model)	Mean value & range (literature)	Publication
<i>Volume doubling time</i>	52 days	45 days (33-150)	Begg & Steel, 2002
<i>Labelling index</i>	5%	7% (5-17)	Steel, 1989
$T_S$ (length of the S phase)	11 hours	10.7 hours (4.4-45.7) 11 hours	Begg et al, 1999 Tannock & Hill, 1998
$T_C$ (cell cycle time)	33 hours (20-60)	$3 \times T_S$	Hall, 2000
<i>Tumour composition</i>	<ul style="list-style-type: none"> <li>▪ CSC</li> <li>▪ Differentiated cells</li> <li>▪ Quiescent cells</li> </ul>	<ul style="list-style-type: none"> <li>▪ Cancer stem cells</li> <li>▪ Cells capable of limited divisions</li> <li>▪ Non-proliferating cells</li> </ul>	Tubiana, 1986  Prince 2007, Moore 2011
<i>Percentage of CSCs in the tumour</i>	5-6% (pre treatment) ? (during treatment)	1.7 – 13.5% (HNC) 12.3% (HNC) 0.4 – 82.7% (other cancers)	Tang 2013 Harper 2007 Huang 2013

# RT: CLINICAL JUSTIFICATION

The RTOG 9003 trial has shown that:

**Hyperfractionated radiotherapy** for advanced head and neck cancer is **the optimal treatment** schedule due to the high rate of locoregional control and no significant increase in late toxicity when compared with standard treatment regimens (Fu et al. 2000, Beitler et al. 2014).


Furthermore, the advantage of hyperfractionation over standard and accelerated radiotherapy has been demonstrated by the meta-analysis undertaken by Bourhis et al. (2006).




# TUMOUR HYPOXIA AND CSC

Experimental findings	References
Hypoxic conditions lead to an increase in the CSC fraction and promote acquisition of stem-like phenotype	<i>AM McCord et al 2009 Mol Cancer Res 7:489</i>
VEGF has higher expression in the CSC subpopulation	<i>S Bao et al 2006 Cancer Res 66:7843</i>
The presence of HIF2 $\alpha$ proteins maintain an undifferentiated phenotype among CSCs (i.e. sustained CSC status)	<i>A Jogi et al 2002 Proc Natl Acad Sci USA 99:7021</i>

# CELL SURVIVAL CURVES UNDER VARIOUS HYPOXIC CONDITIONS




# CSC DISTRIBUTION DURING TREATMENT FOR VARIOUS LEVELS OF HYPOXIA




Obs: It nearly appears that hypoxia keeps the CSC subpopulation under control.

# CSC DIVISION PATTERN



# THE IMPACT OF SYMMETRICAL DIVISION PROBABILITY ON CSC SUBPOPULATION



*Hypoxic level: 6mmHg*


# MODELLING AIMS (II)

To evaluate **inter-patient variation** of tumour response to radiotherapy as a function of:

GROWTH KINETICS

CSC SUBPOPULATION KINETICS


HYPOXIA





# TUMOUR-RELATED PARAMETERS INCLUDED IN THE MODEL

<b>Tumour-related parameters</b>	<b>Values / ranges</b>
<b>Cell cycle time</b>	<b>20h, 33h, 60h</b>
<b>Hypoxia</b>	<b>3mmHg – 10mmHg</b>
<b>Probability of symmetrical division</b>	<b>1.9% - 10%</b>

# HEAD AND NECK TUMOUR GROWTH




*Exponential tumour growth curves for three head and neck cancers with different growth kinetic parameters.*



*Gaussian distribution of cell cycle times around the mean value*




# TUMOUR RESPONSE AS A FUNCTION OF GROWTH KINETICS AND CSC DIVISION PATTERN FOR OXIC TUMOURS



L. Marcu *et al* 2016 *Cell Prolif* (in press)


# INTER-PATIENT VARIATION OF TUMOUR RESPONSE TO RT AS A FUNCTION OF CSC DIVISION PATTERN AND TUMOUR HYPOXIA



# CONCLUSIONS (I)


- Oxic/very mildly hypoxic HNC are controlled by hyperfractionated radiotherapy, irrespective of growth kinetics and CSC division pattern.
- Moderately hypoxic tumours show different responses to radiotherapy as a function of growth kinetics.
- In **rapidly proliferating tumours** the **number of fractions** needed for tumour control **increases exponentially** with the probability of CSC symmetrical division, whereas in **moderately growing** HNC this behaviour **is linear**.

# CSC MARKERS & TREATMENT RESPONSE



R. Tannishtha et al **2001** *Nature* 414, 105-111

# CSC - TARGETING



# ONGOING AND FUTURE WORK

## THEORETICAL LEVEL

- Modelling CSC-targeting through induction of differentiation
- All-trans-retinoic-acid (ATRA)



## EXPERIMENTAL LEVEL

- HNC cell line growth and CSC identification via surface markers
- Cell line irradiation for determination of SF2

# FINAL CONCLUSIONS

- Differences in treatment response of various HNC models due to CSCs and their interplay with growth kinetics show the importance of **CSC identification** within the tumour.
- The need for accurate markers for **CSC labelling** is therefore imminent.
- Both **quantitative and qualitative knowledge on CSC** is needed to describe the resistant subpopulation and to design treatment regimens accordingly.

# TOWARDS PERSONALISED TREATMENT IN HEAD AND NECK CANCER

**REPAIR**

**REPOPULATION**

**REDISTRIBUTION**

**REOXYGENATION**

**RADIORESISTANCE**

**PREDICTIVE** ASSAYS FOR CSCs

IMPROVED OXYGEN **PERFUSION**

**PROTECTION** OF NORMAL TISSUE

**P**ERSONALISED  
**R**ADIO THERAPY



# THANK YOU

## ACKNOWLEDGMENTS

Ministry of National Education, CNCS-UEFISCDI, Project no. PN-II-ID-PCE-2012-4-0067